PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Expands HCV NS3/4A Protease Selection - AnaSpec, Eurogentec Group is pleased to announce the expansion of our NS3/4A protease selection to include proteases from genotypes 1a, 1b, 2a, 3a and 4d
AnaSpec Expands HCV NS3/4A Protease Selection

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2010/12/20 - AnaSpec, Eurogentec Group is pleased to announce the expansion of our NS3/4A protease selection to include proteases from genotypes 1a, 1b, 2a, 3a and 4d.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

These recombinant HCV NS3/4A proteases are highly active and can be used with the SensoLyte® 490, 520, or 620 HCV Protease Assay Kits for screening of anti-HCV protease drugs. HCV NS3 protease is responsible for the cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B sites of the nonstructural protein. It is essential for viral replication and the formation of infectious viral particles, and thus has been considered as one of the most attractive targets for anti-HCV therapy.3-7

Hepatitis C Virus (HCV) belongs to the Flaviviridae family of positive, single stranded RNA. Approximately 170 million people worldwide are infected with this virus and infection results in liver diseases such as chronic hepatitis, cirrhosis and hepatocellular carcinoma.1 Seven major HCV genotypes have been identified which differ in >30 nucleotide sites.2 Genotypes 1, 2 and 3 are found predominantly in the US, Europe, Australia, Japan, Taiwan, Thailand and China; Genotype 4 in the Middle East, Egypt and Central Africa; Genotype 5 in South Africa and Genotype 6 in Southeast Asia.2

AnaSpec, Eurogentec Group also provides HCV NS3/4A mutant proteases. These mutants provide researchers with additional tools to assess the implications and explore a response to the emergence of protease inhibitor resistant NS3 proteases.

Reference:

1. Seeff, LB and JH. Hoofnagle, Hepatology 36, S1 (2002).
2. Imhof, I. and P. Simmonds, J. Virol. 84, 4597 (2010).
3. Sali, DL. et al., Biochem. 37, 3392 (1998).
4. Steinkuhler, C. et al., Biochem. 37, 8899 (1998).
5. Gallinari, P. et al., J. Virol. 72, 6758 (1998).
6. Hardy, RW. et al. J. Virol. 77, 2029 (2003).
7. Hamill, P. and F. Jean, Biochem. 44, 6586 (2005).

About AnaSpec, Eurogentec Group
Since 1993, AnaSpec, Inc. (anaspec.com) is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. As a subsidiary of Eurogentec, AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Expands HCV NS3/4A Protease Selection

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560 t.kao[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)